Focused On-demand Library for Ribonucleoprotein PTB-binding 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8IY67

UPID:

RAVR1_HUMAN

Alternative names:

Protein raver-1

Alternative UPACC:

Q8IY67; A6NMU4; Q8IY60; Q8TF24

Background:

Ribonucleoprotein PTB-binding 1, also known as Protein raver-1, plays a crucial role in the regulation of alternative splicing events. It works in tandem with PTBP1 to influence exon skipping and the selection between mutually exclusive exons, particularly during the maturation of the TPM1 pre-mRNA. This protein's ability to modulate splicing events underscores its importance in RNA processing.

Therapeutic significance:

Understanding the role of Ribonucleoprotein PTB-binding 1 could open doors to potential therapeutic strategies. Its involvement in the precise regulation of alternative splicing presents opportunities for the development of novel interventions in diseases where splicing errors are a contributing factor.